Phaseline

Targets › PKP2

PKP2 (Plakophilin-2): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 3 Phase 1; Cardiovascular; next expected readout Dec 2026.

A component of desmosome cell-cell junctions which are required for positive regulation of cellular adhesion. Regulates focal adhesion turnover resulting in changes in focal adhesion size, cell adhesion and cell spreading, potentially via transcriptional modulation of beta-integrins. (UniProt, Q99959)

Open in Phaseline: the race on PKP2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Lexeo TherapeuticsLX2020
Adeno-associated viral vector (AAVrh.10) encoding human Plakophilin-2 (PKP2) gene
PKP2Phase 1Arrhythmogenic CardiomyopathyDec 2026
Rocket PharmaceuticalsRP-A601
AAV serotype rh.74 vector encoding human plakophilin 2 (PKP2)
PKP2Phase 1PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)Sep 2028
Tenaya TherapeuticsTN-401
AAV9 gene therapy delivering PKP2 transgene
PKP2Phase 1Arrhythmogenic Right Ventricular CardiomyopathyOct 2029

Conditions

Arrhythmogenic Right Ventricular Cardiomyopathy (1) PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) (1) Arrhythmogenic Cardiomyopathy (1)

Modalities

other (3)

Companies

Tenaya Therapeutics (1) Rocket Pharmaceuticals (1) Lexeo Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.